PE20110275A1 - INHIBIDORES DE cMET - Google Patents
INHIBIDORES DE cMETInfo
- Publication number
- PE20110275A1 PE20110275A1 PE2011000152A PE2011000152A PE20110275A1 PE 20110275 A1 PE20110275 A1 PE 20110275A1 PE 2011000152 A PE2011000152 A PE 2011000152A PE 2011000152 A PE2011000152 A PE 2011000152A PE 20110275 A1 PE20110275 A1 PE 20110275A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- halo
- compounds
- alcoxy
- triazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE G ES CR4 O N, DONDE R4 ES H, CN, ALCOXI(C1-C10), ENTRE OTROS; J ES CR5 O N, DONDE R5 ES HALO, TIO, OXI, ENTRE OTROS; K ES CR6 O N, DONDE R6 ES H, HALO, SULFONILO, ENTRE OTROS; M ES CR7 O N, DONDE R7 ES CN, HIDROXI, AMINO, ENTRE OTROS; L ESTA AUSENTE O ES UN ENLAZANTE DE 1 A 6 ATOMOS DE C, O, N Y S; T ES CR8 O N, DONDE R8 ES H, ARILOXI(C4-C12), IMINO, ENTRE OTROS; U ES CR9 O N, DONDE R9 ES CN, TIO, AMIDO, ENTRE OTROS; V ES CR10 O N, DONDE R10 ES H, SULFONAMIDO, ALQUILO(C1-C10), ENTRE OTROS; W ES CR11 O N, DONDE R11 ES HALO, IMINO, ENTRE OTROS; X ES CR12 O N, DONDE R12 ES NITRO, OXI, AMINO, ENTRE OTROS; Y ES CR13 O N, DONDE R13 ES H, CARBONILO, SULFINILO, ENTRE OTROS; Z ES CR14R15 O NR16, DONDE R14 Y R15 SON CADA UNO H, NITRO, CN, ENTRE OTROS; R16 ES H, TIO, OH, ENTRE OTROS; R1 ES H, CARBONILOXI, ALCOXI(C1-C10), ENTRE OTROS; R2 ES H; R3 ES H, ARILOXI(C4-C12), OXAALQUILO(C1-C10), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(6-((3H-[1,2,3]TRIAZOLO[4,5-b]PIRIDIN-3-IL)METIL)IMIDAZO[1,2-a]PIRIDIN-2-IL)-2,2,2-TRIFLUOROACETAMIDA; N-(6-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-3-ILTIO)IMIDAZO[1,2-b]PIRIDAZIN-2-IL)CICLO-PROPANCARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR DE TIROSINA QUINASA cMET SIENDO UTILES EN EL TRATAMIENTO DE CANCER, ATEROESCLEROSIS, FIBROSIS DEL PULMON
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8895908P | 2008-08-14 | 2008-08-14 | |
US11791008P | 2008-11-25 | 2008-11-25 | |
US16100709P | 2009-03-17 | 2009-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110275A1 true PE20110275A1 (es) | 2011-05-08 |
Family
ID=41202532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000152A PE20110275A1 (es) | 2008-08-14 | 2009-08-14 | INHIBIDORES DE cMET |
Country Status (26)
Country | Link |
---|---|
US (1) | US8178534B2 (es) |
EP (1) | EP2313407B1 (es) |
JP (1) | JP5469666B2 (es) |
KR (1) | KR20110039383A (es) |
CN (1) | CN102124005B (es) |
AR (1) | AR072936A1 (es) |
AU (1) | AU2009281822B2 (es) |
BR (1) | BRPI0917808A2 (es) |
CA (1) | CA2731108A1 (es) |
CO (1) | CO6351724A2 (es) |
CR (1) | CR20110135A (es) |
DO (1) | DOP2011000050A (es) |
EA (1) | EA019723B1 (es) |
EC (1) | ECSP11010889A (es) |
ES (1) | ES2608761T3 (es) |
GE (1) | GEP20125652B (es) |
IL (1) | IL210734A0 (es) |
MA (1) | MA32615B1 (es) |
MX (1) | MX2011001732A (es) |
MY (1) | MY150542A (es) |
NZ (1) | NZ590617A (es) |
PE (1) | PE20110275A1 (es) |
TW (1) | TWI455939B (es) |
UY (1) | UY32049A (es) |
WO (1) | WO2010019899A1 (es) |
ZA (1) | ZA201100467B (es) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
US20090197880A1 (en) * | 2007-07-13 | 2009-08-06 | Genelabs Technologies, Inc. | Anti-viral compounds, compositions, and methods of use |
WO2009033702A1 (en) | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
PT2203439E (pt) | 2007-09-14 | 2011-02-11 | Ortho Mcneil Janssen Pharm | 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas |
TW200927731A (en) | 2007-09-14 | 2009-07-01 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
EP2220083B1 (en) | 2007-11-14 | 2017-07-19 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
WO2009128520A1 (ja) * | 2008-04-18 | 2009-10-22 | 塩野義製薬株式会社 | P13k阻害活性を有する複素環化合物 |
EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
CA2760741C (en) | 2009-05-12 | 2018-05-01 | Addex Pharma S.A. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
ES2409006T3 (es) | 2009-05-12 | 2013-06-24 | Janssen Pharmaceuticals Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2 |
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
DK3511330T3 (da) | 2009-12-31 | 2020-12-21 | Hutchison Medipharma Ltd | Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer |
EP2571878B1 (en) * | 2010-05-17 | 2018-10-17 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases |
WO2012003338A1 (en) * | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
CN103958509B (zh) * | 2011-09-15 | 2015-12-23 | 诺华股份有限公司 | 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物 |
BR112014006223A8 (pt) * | 2011-09-15 | 2018-01-09 | Novartis Ag | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação |
CN103030654A (zh) * | 2011-10-09 | 2013-04-10 | 济南赛文医药技术有限公司 | 一种小分子c-Met蛋白激酶抑制剂 |
WO2013135674A1 (en) * | 2012-03-12 | 2013-09-19 | Syngenta Participations Ag | Insecticidal 2-aryl-acetamide compounds |
ME02651B (me) | 2012-06-13 | 2017-06-20 | Incyte Holdings Corp | Substituisana triciklična jedinjenja kao inhibitori fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
CA2909207C (en) | 2013-04-19 | 2021-11-02 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP2995618B1 (en) * | 2013-05-10 | 2019-01-09 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | [1,2,4]triazol [4,3-a]pyridine derivate, preparation method therefor or medical application thereof |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
KR20200036063A (ko) | 2014-01-21 | 2020-04-06 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
JP6629740B2 (ja) | 2014-01-21 | 2020-01-15 | ヤンセン ファーマシューティカ エヌ.ベー. | 代謝型グルタミン酸作動性受容体サブタイプ2の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用 |
JP6602778B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Lsd1阻害剤としてのシクロプロピルアミン類 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
WO2015123408A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
RU2729630C2 (ru) | 2015-06-25 | 2020-08-11 | Тайхо Фармасьютикал Ко., Лтд. | Терапевтическое средство для фиброза |
EP3334709A1 (en) | 2015-08-12 | 2018-06-20 | Incyte Corporation | Salts of an lsd1 inhibitor |
CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
WO2017184934A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
EP3544978B1 (de) | 2016-11-23 | 2020-11-04 | Bayer CropScience Aktiengesellschaft | 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridin-derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel |
HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
CA3053739C (en) | 2017-02-15 | 2023-02-14 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
BR112021011547A2 (pt) | 2018-12-14 | 2021-08-31 | Beta Pharma, Inc. | Compostos substituídos com organofósforos como inibidores de c-met, e seus usos terapêuticos |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8719368D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Heterocyclic compounds |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CA2630884A1 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
RS55630B1 (sr) * | 2005-12-21 | 2017-06-30 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
CA2659971A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
US7683060B2 (en) * | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
BRPI0717320A2 (pt) | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
LT3034075T (lt) * | 2006-11-22 | 2018-11-26 | Incyte Holdings Corporation | Imidazotriazinai ir imidazopirimidinai kaip kinazės inhibitoriai |
PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
WO2009106577A1 (en) * | 2008-02-28 | 2009-09-03 | Novartis Ag | Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
-
2009
- 2009-08-13 UY UY0001032049A patent/UY32049A/es not_active Application Discontinuation
- 2009-08-14 NZ NZ590617A patent/NZ590617A/en not_active IP Right Cessation
- 2009-08-14 ES ES09791542.5T patent/ES2608761T3/es active Active
- 2009-08-14 MX MX2011001732A patent/MX2011001732A/es active IP Right Grant
- 2009-08-14 US US12/541,724 patent/US8178534B2/en not_active Expired - Fee Related
- 2009-08-14 TW TW098127469A patent/TWI455939B/zh not_active IP Right Cessation
- 2009-08-14 KR KR1020117005243A patent/KR20110039383A/ko not_active Application Discontinuation
- 2009-08-14 JP JP2011523198A patent/JP5469666B2/ja not_active Expired - Fee Related
- 2009-08-14 CA CA2731108A patent/CA2731108A1/en not_active Abandoned
- 2009-08-14 WO PCT/US2009/053913 patent/WO2010019899A1/en active Application Filing
- 2009-08-14 GE GEAP200912126A patent/GEP20125652B/en unknown
- 2009-08-14 EA EA201170295A patent/EA019723B1/ru not_active IP Right Cessation
- 2009-08-14 PE PE2011000152A patent/PE20110275A1/es not_active Application Discontinuation
- 2009-08-14 AR ARP090103156A patent/AR072936A1/es unknown
- 2009-08-14 BR BRPI0917808A patent/BRPI0917808A2/pt not_active IP Right Cessation
- 2009-08-14 CN CN200980131456.9A patent/CN102124005B/zh not_active Expired - Fee Related
- 2009-08-14 MY MYPI20110564 patent/MY150542A/en unknown
- 2009-08-14 AU AU2009281822A patent/AU2009281822B2/en not_active Expired - Fee Related
- 2009-08-14 EP EP09791542.5A patent/EP2313407B1/en active Active
-
2011
- 2011-01-18 IL IL210734A patent/IL210734A0/en unknown
- 2011-01-18 ZA ZA2011/00467A patent/ZA201100467B/en unknown
- 2011-02-11 DO DO2011000050A patent/DOP2011000050A/es unknown
- 2011-03-07 MA MA33676A patent/MA32615B1/fr unknown
- 2011-03-11 CO CO11030354A patent/CO6351724A2/es active IP Right Grant
- 2011-03-14 CR CR20110135A patent/CR20110135A/es unknown
- 2011-03-14 EC EC2011010889A patent/ECSP11010889A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009281822B2 (en) | 2014-11-13 |
US20100063054A1 (en) | 2010-03-11 |
EP2313407B1 (en) | 2016-10-05 |
AR072936A1 (es) | 2010-09-29 |
CN102124005A (zh) | 2011-07-13 |
ECSP11010889A (es) | 2011-04-29 |
GEP20125652B (en) | 2012-09-25 |
MY150542A (en) | 2014-01-30 |
AU2009281822A1 (en) | 2010-02-18 |
CA2731108A1 (en) | 2010-02-18 |
MA32615B1 (fr) | 2011-09-01 |
EA201170295A1 (ru) | 2011-08-30 |
CR20110135A (es) | 2011-09-27 |
US8178534B2 (en) | 2012-05-15 |
EA019723B1 (ru) | 2014-05-30 |
WO2010019899A1 (en) | 2010-02-18 |
IL210734A0 (en) | 2011-03-31 |
DOP2011000050A (es) | 2011-03-15 |
EP2313407A1 (en) | 2011-04-27 |
UY32049A (es) | 2010-03-26 |
CN102124005B (zh) | 2014-06-04 |
CO6351724A2 (es) | 2011-12-20 |
JP5469666B2 (ja) | 2014-04-16 |
NZ590617A (en) | 2012-05-25 |
KR20110039383A (ko) | 2011-04-15 |
TW201014857A (en) | 2010-04-16 |
TWI455939B (zh) | 2014-10-11 |
ES2608761T3 (es) | 2017-04-12 |
BRPI0917808A2 (pt) | 2019-09-24 |
JP2012500215A (ja) | 2012-01-05 |
MX2011001732A (es) | 2011-03-25 |
ZA201100467B (en) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110275A1 (es) | INHIBIDORES DE cMET | |
EA201100975A1 (ru) | Производные 1,2,4-оксадиазола и их применение в терапии | |
PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
PE20140390A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
PE20130395A1 (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
PE20080689A1 (es) | Derivados de amina inhibidores de quinasa | |
PE20130234A1 (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
DE602005015833D1 (de) | Imidazopyridin- und imidazopyrimidin-derivate als antibakterielle mittel | |
EA201190303A1 (ru) | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
EA201170770A1 (ru) | Органические соединения | |
PE20090441A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA | |
PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
PE20121482A1 (es) | Derivados de imidazopiridina como inhibidores de jak | |
PE20070978A1 (es) | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) | |
BRPI0410714B8 (pt) | derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso | |
UY30183A1 (es) | Derivados de quinolina | |
EA201190301A1 (ru) | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
PE20140471A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
MX2007014082A (es) | Pirido[2,3-d]pirimidinas utiles como inhibidores del virus de la hepatitis c (hcv), y metodos para la preparacion de las mismas. | |
MX2011011963A (es) | Derivados de 7-aril-1,2,4-triazolo[4,3-a]piridina y uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2). | |
MY140868A (en) | Amide derivatives | |
WO2007091948A3 (en) | Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1 | |
ATE486602T1 (de) | Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |